Advertisement

Drugs

, Volume 47, Issue 1, pp 82–92 | Cite as

Treatment Recommendations for Osteosarcoma and Adult Soft Tissue Sarcomas

  • Piero Picci
  • Stefano Ferrari
  • Gaetano Bacci
  • Franco Gherlinzoni
Practical Therapeutics

Summary

During the past 20 years, dramatic improvements have been obtained in the treatment of localised osteosarcoma of the extremities, both in the rates of disease-free survival and in quality of life.

Twenty years ago 80 to 90% of the patients died, in spite of mutilating surgery, but now about 75% survive and avoid the necessity of amputation. This is due to the introduction of very effective combined treatments, mostly also using preoperative chemotherapy.

One of the major issues is that of intensive preoperative chemotherapy, which improves both limb salvage and survival. A multidisciplinary approach is necessary to obtain good results.

When the role of adjuvant or neoadjuvant chemotherapy is not accurately defined for soft tissue sarcomas, particular emphasis is given to the staging of the diseases and to the important role of local treatment in the survival of these patients. A combination of radiation therapy and surgery is strongly recommended.

Keywords

Soft Tissue Sarcoma Ifosfamide Preoperative Chemotherapy Poor Responder High Dose Methotrexate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alvegard TA, for the Scandinavian Sarcoma Group. Adjuvant chemotherapy with adriamycin in high grade malignant soft tissue sarcomas — a Scandinavian randomized study. Proceedings of the 22nd Annual Meeting of the American Society of Clinical Oncology, p. 125, Los Angeles, May 4–6, 1986Google Scholar
  2. Antman K, Griffin J, Elias A, Socinski MA, Ryan L, et al. Effect of reconbinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. New England Journal of Medicine 319: 593–598, 1988PubMedCrossRefGoogle Scholar
  3. Bacci G, Gherlinzoni F, Picci P, van Horn JR, Jaffe N, et al. Adriamycin- methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. European Journal of Cancer and Clinical Oncology 22: 1337–1344, 1986CrossRefGoogle Scholar
  4. Bacci G, Pagani P, Donati U. Adjuvant chemotherapy associated with surgery in the treatment of osteosarcoma. Italian Journal of Orthopedics and Traumathology 2: 363–374, 1976Google Scholar
  5. Bacci G, Picci P, Avella M, Ferrari S, Casadei R, et al. Effect of intra-arterial versus intra-venous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities. Journal of Chemotherapy 4: 185–195, 1992Google Scholar
  6. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, et al. Primary chemotherapy and delayed surgery for non-metastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high dose of methotrexate (iv) followed by cisplatinum (ia) and adriamycin (iv). Cancer, in press, 1993Google Scholar
  7. Bacci G, Picci P, Pignatti G, De Cristofaro R, Dallari D, et al. Neoadjuvant chemotherapy for non metastatic osteosarcoma of the extremities: the experience at the Rizzoli Institute. Clinical Orthopedics and Related Research 270: 87–98, 1991Google Scholar
  8. Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Rizzoli’s experience in 127 patients treated preoperatively with Methotrexate i.v. (high vs moderate dose) and cisplatinum ia. Cancer 65: 2539–2553, 1990PubMedCrossRefGoogle Scholar
  9. Barkley HT, Martin RG, Romsdahl MM, Lindberg R, Zagars GK. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. International Journal of Radiation Oncology and Biology and Physics 14: 693–699, 1988CrossRefGoogle Scholar
  10. Brant TA, Parsons JT, Marcus RB, Spanier SS, Heare TC, et al. Preoperative irradiation for soft tissue sarcomas of trunk and extremities in adult. International Journal of Radiation Oncology and Biology and Physics 19: 899–906, 1990CrossRefGoogle Scholar
  11. Benjamin RS, Chawla SP, Carrasco C, Raymond AK, Fanning T, et al. Arterial infusion in the treatment of osteosarcoma. In Ryan & Baker (Eds) Recent concepts in sarcoma treatment, pp 269–278, Kluwer Academic Publishers, Dordrecht/Boston/London, 1988CrossRefGoogle Scholar
  12. Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. Journal of Clinical Oncology 10: 1579–1591, 1992PubMedGoogle Scholar
  13. Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A, et al. The treatment of osteosarcoma of the extremities: twenty years’ experience at the Istituto Ortopedico Rizzoli. Cancer 48: 1456–1461, 1981CrossRefGoogle Scholar
  14. Casali P, Zucchinelli P, Pastorino U, Azzarelli A, Santoro A. Epirubicina, Ifosfamide e dacarbazina nei sarcomi delle parti molli in fase avanzata. Argomenti di Oncologia 11: 431–435, 1990Google Scholar
  15. Cortes EP, Holland JF, Wang JJ, Sinks LF, Blom J, et al. Amputation and adriamycin in primary osteosarcoma. New England Journal of Medicine 291: 998–1000, 1974PubMedCrossRefGoogle Scholar
  16. Eilber FR, Giuliano AE, Huth JF, Eckardt J. High grade soft tissue sarcomas of the extremity: UCLA experience with limb salvage. Progress in Clinical and Biological Researches 201: 59–74, 1985Google Scholar
  17. Eilber FR, Giuliano AE, Huth JF, Morton DL. Adjuvant adriamycin in high grade extremity soft tissue sarcomas — a randomized prospective trial. Proceeding of the 22nd Annual Meeting of the American Society of Clinical Oncology, p. 125, Los Angeles, May 4–6, 1986Google Scholar
  18. Eilber FR, Giuliano AE, Huth JF, Weisenburger T, Eckardt J. Intravenous versus intra-arterial adriamycin, 2800r radiation and surgical excision for extremity soft tissue sarcoma: a randomized prospective trial. Proceedings of the 26th Annual Meeting of the American Society of Clinical Oncology, p. 309, Washington, May 20–22, 1990Google Scholar
  19. Elias AD, Rayn L, Aisner J, Antman KH. Doxorubicin, Ifosfamide and DTIC (AID) for advanced untreated sarcomas. Proceedings of the 23rd Annual Meeting of the American Society of Clinical Oncology, p. 134, Atlanta, May 17–19, 1987Google Scholar
  20. Fornasiero A, Daniele O, Ghiotto C, Favaretto A, Fiorentino MV. Adriblastina, Ciclofosfamide ed Interferone (INTRON-A) nei sarcomi delle parti molli in fase avanzata. Argomenti di Oncologia 11: 445–447, 1990Google Scholar
  21. Frustaci S, Foladore S, Lo Re G, De Paoli A, Nascimben O, et al. Ifosfamide ed Epirubicina nei sarcomi delle parti molli avanzati o metastatici. Argomenti di Oncologia 11: 427–430, 1990Google Scholar
  22. Gasparini M, Rouesse J, van Oosterom A, Wagener T, Somers R, et al. Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for research and treatment of Cancer. Cancer Treatment Report 69: 211–213, 1985Google Scholar
  23. Gasparini M, Tondini C, Azzarelli A. Long term evaluation of surgery followed by adjuvant adriamycin in osteogenic sarcoma. European Journal of Cancer and Clinical Oncology 23: 433–436, 1988CrossRefGoogle Scholar
  24. Gherlinzoni F, Bacci G, Picci P, Capanna R, Calderoni P, et al. A randomized trial for the treatment of high grade soft tissue sarcomas of the extremities: preliminary observations. Journal of Clinical Oncology 4: 552–558, 1986PubMedGoogle Scholar
  25. Goorin AM, Delorey M, Gelber R. The Dana Farber Cancer Institute/The Children Hospital adjuvant chemotherapy trials for osteogenic sarcoma: three sequential studies. Cancer Treatment Symposia 3: 155–159, 1985Google Scholar
  26. Goorin AM, Perez-Atayde A, Gebhardt M, Andersen JW, Wilkinson RH, et al. Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/The Children’s Hospital — Study III. Journal of Clinical Oncology 5: 1178–1184, 1987PubMedGoogle Scholar
  27. Jaffe N, Frei E, Traggis D, Bishop J. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. New England Journal of Medicine 291: 994–997, 1974PubMedCrossRefGoogle Scholar
  28. Jaffe N, Paed D, Farber S, Traggis D, Geiser C, et al. Favourable response of metastatic osteogenic osteosarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 31: 1367–1373, 1973PubMedCrossRefGoogle Scholar
  29. Jaffe N, Robertson R, Ayala A, Wallace S, Chuang V, et al. Comparison of intra-arterial Cisdiamminochloroplatinum II with high dose methotrexate and citrovorum factor rescue in the treatment of primary osteogenic sarcoma. Journal of Clinical Oncology 3: 1101–1104, 1985PubMedGoogle Scholar
  30. Jaffe N, Smith D, Jaffe MR, Hudson M, Carrasco H, et al. Intra-arterial cisplatin in the management of stage IIB osteosarcoma in the pediatric and adolescent age group. Clinical Orthopedics and Related Research 270: 15–21, 1991Google Scholar
  31. Krailo M, Ertel L, Makley J, Fryer CS, Baum E, et al. A randomized study comparing high-dose methotrexate with moderate dose methotrexate as components of adjuvant chemotherapy in childhood non-metastatic osteosarcoma. A report from the Children’s Cancer Study Group. Medical Pediatric Oncology 15: 69–77, 1987CrossRefGoogle Scholar
  32. La Vecchia C, De Carli A. Trends in cancer mortality in Italy, 1955–1978. Tumori 71: 201–218, 1985PubMedGoogle Scholar
  33. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, et al. The effect of adjuvant chemotherapy on relapse free survival in patients with osteosarcoma of the extremity. New England Journal of Medicine 314: 1600–1606, 1986PubMedCrossRefGoogle Scholar
  34. Marcove RC, Mike V, Hajeck JV, Levin AG, Hutter RV. Osteogenic sarcoma under the age 21: a review of 145 operative cases. Journal of Bone and Joint Surgery (Am) 52: 411–418, 1970Google Scholar
  35. Mercuri M, Biagini R, Ruggieri P, Campanacci M. Techniques of resection and reconstruction in the treatment of osteosarcoma. Seminar in Orthopedics 3: 71–80, 1988Google Scholar
  36. Meyers PA, Heller G, Healey J, Huvos A, Lane J, et al. Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering Experience. Journal of Clinical Oncology 10: 5–15, 1992PubMedGoogle Scholar
  37. Missenard G, Dubousset J, Kalifa C. Management of osteosarcoma in children and adolescent. Proceedings of International Meeting on Osteosarcoma and Adult Soft Tissue Sarcomas: present trends, p. 37, Aviano (Italy), March 21–22, 1991Google Scholar
  38. Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/III study of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer and Clinical Oncology 23: 1477–1483, 1987CrossRefGoogle Scholar
  39. Ochs JJ, Freeman AI, Douglass HO, Higby DS, Mindell ER, et al. Cis dichlorodiammine-platinum (II) in advanced osteogenic sarcoma. Cancer Treatment Report 62: 239–245, 1978Google Scholar
  40. Picci P, Bacci G, Ferrari S, Sangiorgi R, Casadei R, et al. Local recurrence after limb salvage procedures for osteosarcoma: correlation with margins and chemotherapy induced necrosis. Journal of Bone and Joint Surgery 211 (Suppl. 2): 211, 1993Google Scholar
  41. Picci P, Capanna R, Bacci G, Mercuri M, Ruggieri P, et al. Margins, necrosis and local recurrence after conservative surgery in osteosarcoma. Chirugia degli Organi di Movimento 75 (Suppl. 1): 82–85, 1990Google Scholar
  42. Potter DA, Glenn J, Kinsella T, Glatstein E, Lack EE, et al. Patterns of recurrence in patients with high grade soft tissue sarcomas. Journal of Clinical Oncology 3: 353–366, 1985PubMedGoogle Scholar
  43. Powers BE, Withrow SJ, Thrall DE, Straw RC, Larue SM, et al. Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer 67: 126–134, 1991PubMedCrossRefGoogle Scholar
  44. Provisor A, Nachman J, Krajlo M, Ettiger L, Hammond D. Treatment of non-metatastic osteogenic sarcoma of the extremities with pre-and post-operative chemotherapy. Proceedings of the 23rd Annual Meeting of the American Society of Clinical Oncology, p. 217, Atlanta, May 17–19, 1987Google Scholar
  45. Rock M, Miser J, Pritchard D, Sim F, Shives T. Osteosarcoma; Current Mayo Clinic experience. Proceedings of International Meeting on Osteosarcoma and Adult Soft Tissue Sarcomas: present trends, p. 33, Aviano, Italy, March 21–22, 1991Google Scholar
  46. Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics 8: 659–664, 1985PubMedGoogle Scholar
  47. Rosen G, Caparros B, Huvos AG, Kosloff L, Niremberg A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of primary tumor to preoperative chemotherapy. Cancer 49: 1221–1230, 1982PubMedCrossRefGoogle Scholar
  48. Rosen G, Marcove RC, Caparros B, Niremberg A, Kosloff L, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43: 2163–2177, 1979bPubMedCrossRefGoogle Scholar
  49. Rosen G, Nirenberg A, Jurghens H. Phase II trial of cisplatinum in osteogenic sarcoma. Proceedings of the American Society of Clinical Oncology 20: 363, 1979aGoogle Scholar
  50. Rosenberg SA, Chabner BA, Young RC. Treatment of osteogenic sarcoma: effect of adjuvant high dose methotrexate after amputation. Cancer Treatment Report 63: 739–751, 1979Google Scholar
  51. Rosenberg SA, Suit HD, Baker LH. Sarcomas of soft tissue. In De Vita et al. (Eds) Cancer: principles and practice of oncology, 2nd ed., pp. 1243–1291, JB Lippincott Co, Philadelphia, 1985Google Scholar
  52. Saeter G, Alvegard TA, Elomaa I. Stenwig AE, Holmstrom T, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single agent high dose Methotrexate: a Scandinavian Sarcoma Group Study. Jounal of Clinical Oncology 9: 1766–1775, 1991Google Scholar
  53. Spanier S, Shuster J, Van der Griend RA. The effect of local extent of the tumor on prognosis in osteosarcoma. Jornal of Bone and Joint Surgery (Am) 172: 643–653, 1990Google Scholar
  54. Suit HD, Mankin HJ, Wood WC, Gebhardt MC, Harmon DC, et al. Treatment of patients with stage M0 soft tissue sarcomas. Journal of Clinical Oncology 6: 854–862, 1988PubMedGoogle Scholar
  55. Suit HD, Mankin HJ, Wood WC, Proppe KH. Pre-operative, intraoperative and post-operative radiation in the treatment of primary soft tissue sarcomas. Cancer 55: 2659–2667, 1985PubMedCrossRefGoogle Scholar
  56. Suit HD, Proppe KH, Mankin HJ. Radiation therapy and conservative surgery for sarcoma of soft tissue. Progress in Clinical Cancer 8: 311–318, 1982PubMedGoogle Scholar
  57. Taylor WF, Ivins JC, Dahlin DC, Edmonson JH, Pritchard DJ. Trends and variability in survival of osteosarcoma. Mayo Clinic Proceedings 53: 695–700, 1982Google Scholar
  58. Toma S, Palumbo R, Sogno G, Venturino A, Santi L. Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. Annals of Oncology 3 (Suppl. 2): 119–123, 1992CrossRefGoogle Scholar
  59. Uribe-Botero G, Russel WO, Sutow WW. Primary osteosarcoma of the bone. A clinico-pathologic investigation of 243 cases with necroscopy study in 24. American Journal of Clinical Pathology 67: 427–435, 1977PubMedGoogle Scholar
  60. Wang JJ, Cortes EP, Sinks LF, Holland JE Therapeutic effect and toxiticy of adriamycin in patients with disseminated disease. Cancer 28: 837–843, 1971PubMedCrossRefGoogle Scholar
  61. Winkler K, Beron G, Delling G, Heise U, Kabisch H, et al. Neoadjuvant chemotherapy of osteosarcoma. Results of a randomized cooperative trial (Coss-82) with salvage chemotherapy based on histological tumor response. Journal of Clinical Oncology 6: 329–336, 1988PubMedGoogle Scholar
  62. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. Journal of Clinical Oncology 2: 617–624, 1984PubMedGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Piero Picci
    • 1
  • Stefano Ferrari
    • 2
  • Gaetano Bacci
    • 2
  • Franco Gherlinzoni
    • 3
  1. 1.Laboratorio di Ricerca OncologicaIstituti Ortopedici RizzoliBolognaItaly
  2. 2.Department of ChemotherapyRizzoli Orthopedic InstituteBolognaItaly
  3. 3.5th Department of OrthopaedicsRizzoli Orthopedic InstituteBolognaItaly

Personalised recommendations